Company
Dynavax Technologies
Dynavax Technologies has 14 drugs tracked on RxWires: 3 in Phase 3, 3 in Phase 2, 2 in Phase 1/2, 5 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| HEPLISAV | Phase 3 | End Stage Renal Disease |
| HEPLISAV-B | Phase 3 | Chronic Kidney Disease |
| HEPLISAV and/or Placebo | Phase 3 | Hepatitis B |
| Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate | Phase 2 | Rhinitis, Allergic, Seasonal |
| Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate | Phase 2 | Rhinitis, Allergic, Seasonal |
| rF1V-1018 | Phase 2 | Plague, Pneumonic |
| SD-101 | Phase 1/2 | B-cell Lymphoma |
| Z-1018 | Phase 1/2 | Shingles |
| 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen | Phase 1 | Hepatitis B |
| DV-601 | Phase 1 | Hepatitis B, Chronic |
| 1018 ISS immunostimulatory oligonucleotide | Phase 1 | Colorectal Neoplasms |
| Nivolumab | Phase 1 | Metastatic Pancreatic Adenocarcinoma |
| DV281 | Phase 1 | Advanced Non Small Cell Lung Cancer |
| Adjuvanted Hepatitis B Vaccine | Not Applicable | Hepatitis B Virus |
Latest
No recent events.
Follow Dynavax Technologies on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.